DexCom, Inc. (NASDAQ:DXCM) Holdings Cut by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich lowered its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.5% during the fourth quarter, Holdings Channel reports. The firm owned 92,471 shares of the medical device company’s stock after selling 1,369 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in DexCom were worth $7,490,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of DXCM. Versant Capital Management Inc acquired a new position in DexCom in the 4th quarter valued at $25,000. Private Trust Co. NA grew its position in DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares during the last quarter. Heck Capital Advisors LLC acquired a new stake in DexCom in the 4th quarter worth $38,000. SBI Securities Co. Ltd. acquired a new stake in DexCom in the 4th quarter worth $49,000. Finally, Midwest Capital Advisors LLC acquired a new stake in DexCom in the 4th quarter worth $54,000. Institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In other news, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,083 shares of company stock worth $3,309,794. 0.30% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on DXCM. Canaccord Genuity Group lifted their target price on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and boosted their price target for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Finally, Wells Fargo & Company boosted their price target on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $99.82.

DexCom Stock Down 2.1 %

Shares of NASDAQ:DXCM opened at $77.84 on Monday. The company has a 50 day moving average price of $84.83 and a two-hundred day moving average price of $77.01. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a market capitalization of $30.42 billion, a PE ratio of 54.43, a PEG ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.